Eli Lilly has called on financial regulators ... The issue was also alluded to by Lilly’s chief financial officer, Anat Ashkenazi, on the company’s fourth-quarter results call yesterday ...
As revenues for Eli Lilly’s popular weight loss drug Zepbound continue ... while interim CFO Gordon Brooks received $2.7 million. Anat Ashkenazi, who left the company to become CFO at Alphabet in July ...
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced today that Anat Ashkenazi has resigned from her position as Chief... San Francisco, June 5 (IANS) Google (NASDAQ:GOOGL) parent Alphabet ...
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...
Eli Lilly experienced a 6% increase in price over the last quarter, coinciding with several major developments. The company reported strong financial results, with significant year-over-year ...
Eli Lilly is broadening its direct-to-consumer approach by partnering with a digital health company, Noom, which is focused on weight management. The collaboration connects Noom users with Eli ...
Eli Lilly said an experimental drug nearly eliminated an inherited type of bad cholesterol at its highest dose in a mid-stage study. Eli Lilly on Sunday said the Phase 2 study of lepodisiran ...
The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will prevent heart attacks and strokes. By Gina Kolata As many as one in five ...
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...
Eli Roth‘s The Horror Section has acquired “Jimmy and Stiggs,” marking the horror company’s first major deal since launching earlier this month, Variety can exclusively report. Directed ...